Neotracin(5 mg+250 IU)/gm

Neotracin is a topical antibacterial combination used for the prevention and treatment of minor bacterial skin infections.

Established/Approved Uses

• Prophylaxis against infection in minor cuts, scrapes, and burns.
• Treatment of superficial skin infections caused by susceptible bacteria (e.g., minor infected dermatitis, impetiginous lesions).

Guideline-Supported / Adjunct Uses

• As an adjunct to systemic antibiotic therapy in certain pyodermas such as impetigo, when a treating physician determines topical therapy is appropriate.
• Short-term topical care of infected or potentially infected dermatoses (e.g., infected eczema, contact dermatitis) under medical supervision.

Neotracin is intended only for minor, superficial wounds and is not appropriate for deep puncture wounds, animal bites, or serious burns, which require prompt medical evaluation.

Each gram of ointment typically contains Neomycin Sulfate (equivalent to a defined amount of neomycin base, commonly around 3.5 mg neomycin base per gram) and Bacitracin Zinc (commonly around 400-500 units per gram), in a suitable ointment base. Neomycin Sulfate + Bacitracin Zinc is formulated for topical application only. Exact strengths vary by manufacturer/brand; refer to the specific product label.

Neotracin is a fixed-dose combination topical antibacterial product that pairs two antibiotics with complementary spectra of activity. Neomycin sulfate is an aminoglycoside antibiotic active mainly against gram-negative aerobic bacteria and some staphylococci, while bacitracin zinc is a polypeptide antibiotic active mainly against gram-positive organisms such as staphylococci and streptococci. Combined, they provide broader topical antibacterial coverage than either agent alone. Neotracin is available as an ointment (and in some markets as a topical powder) for use on minor skin wounds and superficial infections.

Neotracin belongs to the therapeutic class of Topical Antibiotics / Topical Antibacterial Combinations, used in dermatological and wound-care preparations.

Neomycin Sulfate + Bacitracin Zinc combines two antibiotics with distinct mechanisms of action:

By combining these two agents, Neomycin Sulfate + Bacitracin Zinc provides broader antibacterial coverage against common skin pathogens than either component used alone.

Neotracin is for external (topical) use on the skin only. Wash hands before and after application. Gently clean the affected area and pat dry, then apply a thin layer of ointment; a sterile dressing/bandage may be used if advised by a physician. Avoid contact with the eyes, mouth, nose, and other mucous membranes, and avoid inhalation. Do not apply to the eyes unless a specific ophthalmic-labeled formulation has been prescribed by a physician. Do not use on large open wounds, deep puncture wounds, animal bites, or serious burns without medical evaluation.

Neotracin is applied topically, so systemic drug interactions are uncommon when used as directed on limited areas of intact or minimally broken skin. However, clinically relevant interactions can occur, particularly with extensive application, use on large denuded areas, or prolonged use:

• Other nephrotoxic or ototoxic agents (e.g., other aminoglycosides, vancomycin, amphotericin B, cisplatin, potent loop diuretics): concurrent systemic use with extensive topical application of Neotracin may theoretically increase the risk of additive nephrotoxicity or ototoxicity due to systemic absorption of neomycin, especially when applied to large wound areas.
• Neuromuscular-blocking agents: both neomycin and bacitracin components have been associated with neuromuscular blockade when absorbed systemically in significant amounts; caution is advised if Neotracin is applied over large areas in patients receiving these agents.

Because systemic absorption from intact or minimally broken skin is minimal, clinically significant interactions are rare with normal topical use, but a physician or pharmacist should be informed of concurrent nephrotoxic or ototoxic drug use before extensive or prolonged application.

Most patients tolerate Neotracin well when used as directed. Reported side effects include:

Common

• Mild, transient burning, stinging, itching, or redness at the site of application.

Less Common / Important

• Allergic contact dermatitis - itching, redness, rash, or worsening skin irritation; more frequently associated with the neomycin component.
• Delayed wound healing if used inappropriately on larger wounds.
• Rarely, generalized allergic reactions, including swelling and, very rarely, anaphylaxis (more often reported with bacitracin) - discontinue immediately and seek medical attention if this occurs.
• Overgrowth of non-susceptible organisms (including fungi) with prolonged use.

Discontinue Neotracin and consult a physician if a rash, worsening irritation, or signs of an allergic reaction develop.

Neotracin has not been formally established as safe for use during pregnancy. Systemic absorption from topical use on intact or minimally broken skin is generally minimal; however, Neotracin should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. A physician should be consulted before use during pregnancy, particularly if application is anticipated over large or extensively broken skin areas.

It is not known whether topically applied components of Neotracin are excreted in human breast milk in clinically significant amounts. Caution is advised, and a physician should be consulted before use while breastfeeding, especially if applied near the breast/nipple area or over large areas.

Neotracin is for external use only and the following precautions should be observed:

• Not for use in the eyes unless a specific ophthalmic-labeled formulation has been prescribed; accidental eye contact should be managed by rinsing thoroughly with water and seeking medical advice if irritation persists.
• Do not use for deep or puncture wounds, animal or human bites, or serious burns without prior medical evaluation.
• Discontinue use and consult a physician if a rash, itching, redness, swelling, or worsening irritation develops, as this may indicate allergic contact sensitization.
• Prolonged or repeated use may result in overgrowth of non-susceptible organisms, including fungi; if superinfection occurs, discontinue and seek appropriate treatment.
• If the condition does not improve within 7 days, or if it worsens, stop use and consult a physician.
• Avoid applying over large areas of the body or for prolonged periods without medical supervision, as systemic absorption and associated risks (including ototoxicity or nephrotoxicity) increase with extensive or prolonged use, especially on damaged skin.
• Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Topical overdose of Neotracin is unlikely with normal use, but excessive or prolonged application, especially over large or broken skin areas, may increase the risk of local irritation, allergic sensitization, or (rarely) systemic absorption leading to effects such as ototoxicity or nephrotoxicity. If accidental ingestion occurs, or if signs of a serious allergic reaction (e.g., difficulty breathing, swelling of the face/throat, severe rash) or systemic toxicity develop, seek immediate medical attention or contact a poison control center/emergency services without delay. Do not attempt to manage a suspected overdose or serious reaction at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Keep the container tightly closed and avoid contaminating the tip of the tube.

Pediatric Patients

Neotracin may be used in children under medical guidance; dose and frequency may need to be reduced compared to adults. Use in neonates and very young infants is not recommended due to limited safety data and a theoretically higher risk of systemic absorption through thinner skin. Safety and efficacy in neonates have not been established.

Elderly Patients

No specific dose adjustment is generally required for elderly patients using Neotracin topically on limited areas; however, elderly patients with thin or fragile skin, or with extensive wounds, should be monitored for local irritation and signs of sensitization.

Renal or Hepatic Impairment

Formal dose-adjustment guidance is not established for topical Neotracin, as systemic absorption is normally minimal. However, caution is advised in patients with renal impairment if the product is applied over large or extensively damaged skin areas, given the potential nephrotoxicity associated with systemically absorbed neomycin.

For prophylactic use on minor cuts, scrapes, and burns, Neotracin is typically used for a short period, generally up to 7 days, or until the wound has healed. For treatment of a diagnosed superficial infection, duration should be determined by a physician, generally not exceeding 7-10 days of continuous use unless otherwise directed. If there is no improvement within 7 days, or if symptoms worsen, treatment should be stopped and a physician consulted. Prolonged use beyond the recommended duration is not advised due to the risk of allergic sensitization and superinfection with non-susceptible organisms.

Neomycin Sulfate + Bacitracin Zinc belongs to the drug classes: Aminoglycoside Antibiotic (Neomycin Sulfate) combined with Polypeptide Antibiotic (Bacitracin Zinc), formulated as a Topical Antibacterial Combination.

Neomycin Sulfate + Bacitracin Zinc exerts its antibacterial effect through two complementary mechanisms. Neomycin sulfate is bactericidal, binding to the 30S ribosomal subunit of susceptible bacteria and causing misreading of the genetic code, which halts bacterial protein synthesis; it is primarily active against gram-negative aerobic bacteria and some staphylococci. Bacitracin zinc is also bactericidal, acting by inhibiting the dephosphorylation and recycling of the lipid pyrophosphate carrier molecule required for bacterial cell wall (peptidoglycan) synthesis; it is primarily active against gram-positive organisms such as staphylococci and streptococci. Together, the two components of Neomycin Sulfate + Bacitracin Zinc provide a broader spectrum of topical antibacterial activity than either agent alone.

Neotracin may be used topically in children for the same indications as in adults, under medical guidance, generally using the smallest effective amount for the shortest necessary duration. Use in neonates and very young infants is not recommended, and safety and efficacy in this age group have not been established, due to the potential for increased systemic absorption through immature or thinner skin and consequent risk of toxicity. A physician should be consulted before using Neotracin in infants and young children, particularly for wounds covering a large body surface area.